JRGD:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - Global Research Enhanced Index Equity UCITS ETF - USD (dist) (EUR)

ETF | Others |

Last Closing

USD 39.79

Change

0.00 (0.00)%

Market Cap

USD 2.00M

Volume

2.73K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

+0.01 (+0.02%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

-2.36 (-2.65%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.27 (-1.30%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.12 (-1.01%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.07 (-1.51%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.31 (-1.50%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.31 (-2.68%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.28 (-0.52%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.32 (-3.43%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

-0.93 (-0.78%)

USD 12.26B

ETFs Containing JRGD:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.23% 22% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.23% 23% F 24% F
Trailing 12 Months  
Capital Gain -3.26% 33% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.26% 36% F 39% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.25% 65% D 65% D
Dividend Return 10.25% 64% D 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.22% 56% F 64% D
Risk Adjusted Return 91.32% 78% C+ 81% B-
Market Capitalization 2.00M 1% F 1% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.